NCT05643235
Implanted Loop Recorders for Detection and Management of Arrhythmia With Bruton Tyrosine Kinase Inhibitors
At risk: Primary completion moved 12 months later.
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 4 versions: 4 with changes below. See every version on ClinicalTrials.gov ↗
Notable Primary completion pushed from Dec 1, 2026 to Dec 1, 2027 Show 4 more changesShow less
- Eligibility criteria expanded, about 13 words
- Secondary endpoints: details revised at 3 of 4 entries
- Site details revised
- Publications: details revised at 14 of 17 entries
- Notable Primary completion date: May 1, 2025 to Dec 1, 2026v3
- Notable Primary completion date: May 1, 2024 to May 1, 2025
- Start date: Nov 1, 2022 to Jan 1, 2023
- Study completion date: Nov 1, 2027 to Dec 1, 2030
- Study First Submitted
- Notable: the plan changed
Endpoints
Primary
Incidence of device detected atrial fibrillation (AF)
Timeframe: at 18 months after start of BTK inhibitor
Long term Incidence of device detected AF
Timeframe: up to 60 months after device implantation
Secondary (4)
Incidence of device detected ventricular arrhythmia (VA)
BTK dose reduction or discontinuation due to device detected arrhythmia, assessed by chart review.
Initiation of anticoagulation for AF detected by device monitoring, assessed by chart review
Long term incidence of device detected ventricular arrhythmia (VA)
Arms and interventions
Patients initiated on Bruton tyrosine kinase inhibitors, consenting to installment of ILROther
Patients free of documented arrhythmia initiating treatment with a BTK inhibitor who consent to monitoring using the Medtronic LINQ-2 implanted cardiac monitoring device (ILR) prior to initiating BTK inhibitor therapy.
Devices: Medtronic LINQ-2 Insertable Cardiac Monitor (ILR)
Sites
1 site in 1 country
- Northwell (Northshore University/Long Island Jewish Hospitals)New Hyde Park, New York, United States